AICDA and Hodgkins lymphoma: So, leniolisib correlation with Hodgkin’s lymphoma remains currently a mere inductive speculation, first of all because leniolisib could normalise AID under-activation, rather than causing its over-activation, in APDS patients, and ultimately AID levels were not evaluated in the #NCT02435173 clinical trial cohort (33, 35, 36).